Ousia Pharma Secures Substantial Seed Financing Led by Omega Funds to Advance Groundbreaking Obesity Treatment

Ousia Pharma and Omega Funds Denmark Finland France Germany Netherlands Sweden United Kingdom Massachusetts

Pioneering a first-in-class drug-targeting approach that leverages hormone analogues to deliver small-molecule neuroplasticity modulators directly to the brain's appetite control centersFinancing will support the development of a dual-incretin-NMDA receptor antagonist conjugate through preclinical and early clinical development for the treatment of obesityfor additional information.

Contacts

Ousia Pharma
Anders Bue Klein
Co-founder & CEO, Ousia Pharma
E-mail: [e-mail]

Omega Funds
Otello Stampacchia
Managing Director, Omega Funds
E-mail: [e-mail]

 

Logo - https://mma.prnewswire.com/media/2679691/Ousia_Pharma_logo.jpg 
Logo - https://mma.prnewswire.com/media/2679692/Omega_Funds_Logo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/ousia-pharma-secures-substantial-seed-financing-led-by-omega-funds-to-advance-groundbreaking-obesity-treatment-302446485.html